Human papillomavirus infection

Qvin™ Introduces Q-Pad™: Transforming Women's Health with FDA-Cleared Lab Testing using Menstrual Blood

Retrieved on: 
Monday, January 8, 2024
Menopause, Biotechnology, Woman, Research, FDA, Anemia, Health, Diabetes, Fetal hemoglobin, HPV, SAN, Fertility, Stanford University, Obstetrics, Endometriosis, Biomarker, A1C, Patient, Safety, Prediabetes, OTC, Gynaecology, Physician, Human papillomavirus infection

SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ -- Qvin™, the biotechnology research company that developed the first and only healthcare service that collects menstrual blood samples as an alternative to traditionally collected venous blood draws, today announced FDA clearance of its Q-Pad™ and A1c Test. The clearance makes it possible for the millions of women in America who live with diabetes to receive monitoring of A1c, using laboratory tests performed on the Q-Pad. More broadly, this marks an opportunity for testing important biomarkers for the more than 80 million people who menstruate in the U.S.

Key Points: 
  • The traditional methods of blood testing require invasive procedures administered by medical professionals, and those can be time-consuming and expensive.
  • And yet, menstrual samples had never previously been explored as a diagnostic source for health information.
  • "Utilizing menstrual samples, the Q-Pad can address critical women's health issues that have historically been neglected," stated Søren Therkelsen, Co-founder of Qvin.
  • "For instance, women seeking to understand their fertility status can soon monitor various reproductive hormones via menstrual blood using the Q-Pad.

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Retrieved on: 
Friday, January 5, 2024
Book, Immune system, IND, PD-1, HBV, HPV, Prostate cancer, Nivolumab, Record, Clinical trial, Cancer, NUC, Bank statement, SNAP, Hepatitis B virus, Human papillomavirus infection, Safety, Autoimmunity, APOLLO, Vaccine

OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives.

Key Points: 
  • OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives.
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • “2024 promises to be another exciting year for Barinthus Bio, with multiple data readouts expected across our hepatitis B virus (HBV) infection, human papillomavirus (HPV) infection and prostate cancer programs, as well as the planned initiation of the first in human study of our SNAP platform-based candidate VTP-1000 in Celiac Disease,” said Gemma Brown, Chief Financial Officer of Barinthus Bio.
  • * Barinthus Bio has worldwide rights for all product candidates.

Confusion about insurance coverage for cervical cancer screenings contributes to missed screening

Retrieved on: 
Wednesday, January 3, 2024
Testicular cancer, Affordable Care Act, PAP, Risk, Immune system, HIV/AIDS, Woman, Breast cancer, Cervical cancer, Colorectal cancer, WHO, Health, Lung cancer, HPV, Prostate cancer, Vaccination, Cancer, Skin cancer, Human papillomavirus infection, Confusion, Insurance, Letter, HIV, World Health Organization, Conditional sentence, Care Act 2014, Medicaid, Oral cancer, USPSTF, Birth control

The 2023 survey shows 41% of American women are not up to date on cervical cancer screenings.2 This indicates an urgent need to discuss the cost of cervical cancer screening, as many people may be unaware cervical cancer screenings are covered through Medicaid and most private insurance plans.

Key Points: 
  • The 2023 survey shows 41% of American women are not up to date on cervical cancer screenings.2 This indicates an urgent need to discuss the cost of cervical cancer screening, as many people may be unaware cervical cancer screenings are covered through Medicaid and most private insurance plans.
  • That means, under current law, if you have health insurance and you have a cervix, your cervical cancer screenings are covered.
  • The elimination of cervical cancer will be severely hindered without proper education across all populations about screening, insurance coverage and HPV vaccination.
  • 2The cancer screenings studied in this survey were for breast cancer, cervical cancer, colorectal cancer, oral cancer, lung cancer, prostate cancer, skin cancer and testicular cancer.

Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays

Retrieved on: 
Friday, November 10, 2023
QAP (Colombia), BIT, OTCQX, UBM, Patient, PCR, Infection, Therapy, Human papillomavirus infection, Cancer, Business, TSX, HPV, SVP, Vaccine, Ulisse

Molecular (i.e., “PCR”) HPV Assays are used to diagnose infections and distinguish between the virus types that generate higher or lower risks of fatal cancers.

Key Points: 
  • Molecular (i.e., “PCR”) HPV Assays are used to diagnose infections and distinguish between the virus types that generate higher or lower risks of fatal cancers.
  • However, HPV Assays must be stringently monitored to ensure their accuracy – ideally with Microbix QAPs.
  • Ulisse has validated Microbix’s HPV QAPs as tools to support the ongoing accuracy of its HPV Assays and will recommend their usage in its instructions for use (“IFUs”).
  • Additionally, Microbix has created custom ONBOARDx™ kits of QAPs to assist the Ulisse sales teams in demonstrating the HPV Assays to prospective customers, as well as for training operators and for qualifying new HPV Assay installations.

HSS Presents New Reproductive Health Research at the ACR Convergence 2023

Retrieved on: 
Tuesday, November 14, 2023
Knowledge, Woman, Cervical cancer, Contraindication, Patient, Rheumatoid arthritis, Documentation, SLE, Infertility, Diagnosis, Rheumatology, Rheumatism, Fertility, Prevalence, Menopause, Vaccination, Cryopreservation, Flare, DSM-IV codes, Birth, Connective tissue, Hospital for Special Surgery, Doctor of Public Health, Female, Fetus, Smoking, Senior counsel, RD, SAN, Menstrual cycle, Weill Cornell Medicine, Immunosuppression, Risk, History, Hysterectomy, Inflammatory arthritis, Lupus, HSS, PAP, Fertilisation, OOC, Research, Human papillomavirus infection, Ageing, Scleroderma, Systemic scleroderma, Vaccine, American College, American College of Rheumatology, COVID-19, Fertility preservation, MPH, ACR, HPV, Hospital, Birth control, Nursing, Food delivery, MD

Additional research is planned to assess whether demographics, lifestyle and medical conditions may influence this potential association.

Key Points: 
  • Additional research is planned to assess whether demographics, lifestyle and medical conditions may influence this potential association.
  • This study surveyed women of reproductive age with systemic rheumatic disease about their use of contraceptives.
  • Data were collected on 249 women with reproductive capacity, including 147 with inflammatory arthritis and 102 with lupus-like disorders.
  • This study used data from the electronic health record of patients diagnosed with a rheumatic disease in adolescence, seen at HSS, to look at factors associated with HPV vaccination.

Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting

Retrieved on: 
Tuesday, November 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Neoplasm, Human papillomavirus infection, Cervical cancer, Mouse, Anemia, CIN, Therapy, RNA, HPV, Cervical intraepithelial neoplasia, CD47, Immortalised cell line, Cell, Protein, Engineering, SITC, Immunotherapy, HPV16, Messenger, Animal, Society, Alpha globulin, Patient, Vivo, Vaccine, Nutcracker

These data were presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting.

Key Points: 
  • These data were presented at the Society for Immunotherapy of Cancer’s (SITC’s) 38th Annual Meeting.
  • Anemia is the most common adverse effect of CD47-targeting molecules, since red blood cells also express CD47.
  • Moreover, modifying the RNA sequence of the prospective anti-CD47 molecule is far more efficient than engineering the final protein product.
  • Our platform has made it possible for Nutcracker to lay a strong and early foundation for our future therapeutic work.”

Europe Cervical Cancer Screening Market Size, Analysis & Forecasts Report 2023: An $11.45 Billion Market by 2028 - Focus on UK, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 31, 2023
Health, Oncology, Other Health, Government, Human papillomavirus infection, Cardinal Health, Cervical cancer, Incidence, HPV, Mortality, Research, Cell, Abbott Laboratories, Roche, Quest Diagnostics, Siemens, Woman, Collection, PAP, Vaccine, Birth control, Growth, EU

The European cervical cancer screening industry is primarily led by key market players like Abbott Laboratories, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health.

Key Points: 
  • The European cervical cancer screening industry is primarily led by key market players like Abbott Laboratories, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health.
  • These companies play a crucial role in shaping the industry landscape and driving advancements in cervical cancer screening technologies.
  • This aspect is expected to be a driving force behind the growth of the cervical cancer diagnostic testing market in Europe.
  • The increasing incidence of cervical cancer has heightened the demand for screening tests among women, underscoring the importance of regular cervical cancer screening as a preventive measure.

Abbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Retrieved on: 
Thursday, November 2, 2023
University, FDA, Human papillomavirus infection, Emergency Use Authorization, Cervical cancer, NYSE, Food, Infection, SARS-CoV-2, Physician, HPV, Pathology, Genotype, STI, PCR, Health, Hepatitis B, Aline Betancourt, CDC, HIV, Risk, HCV, Cancer, Risk assessment, HR, HIV-1, CMV, Woman, Hepatitis, EBV, Patient, Food and Drug Administration, HBV, Vaccine, Cytomegalovirus

There are many different strains of HPV, each with a unique genetic signature or genotype.

Key Points: 
  • There are many different strains of HPV, each with a unique genetic signature or genotype.
  • However, some commonly used HPV tests are not approved for primary screening and only deliver limited information regarding which of the many different genotypes of HPV are present.
  • The Alinity m high risk (HR) HPV assay is approved as a test for HPV detection and for use in routine cervical cancer screening as per professional medical guidelines.
  • "The Alinity m HR HPV assay was carefully designed to support patient care and streamline HPV testing."

LOLI PHARMA USA Launches Pervistop™: A Groundbreaking Solution for Persistent HPV Management

Retrieved on: 
Tuesday, October 31, 2023
Cervical cancer, Human papillomavirus infection, Hope, HPV, Prevalence, Research, Folate, EGCG, Shijiazhuang Pharma Group, Hyaluronic acid, Woman, Vitamin B12, Infection, Vaccine, Fine chemical, Amazon

Pharma Group, announces the launch of Pervistop™, a breakthrough healthcare solution for persistent HPV (Human Papillomavirus) infections.

Key Points: 
  • Pharma Group, announces the launch of Pervistop™, a breakthrough healthcare solution for persistent HPV (Human Papillomavirus) infections.
  • This milestone reflects the company's long-standing commitment to evidence-based products and marks its entry into the US HPV management market.
  • Pervistop™, a dietary supplement specifically formulated for persistent HPV management, represents a significant advancement in addressing this health concern.
  • Our entry into the HPV management arena signifies our dedication to improving the lives of individuals affected by this persistent health issue.

Microbix QAPs Supporting HPV Testing in Ireland

Retrieved on: 
Friday, October 27, 2023
System, Cervical cancer, Thorpe Coombe Hospital, MDX, OTCQX, HPV, Business development, QAP (Colombia), Senior, Republic, MSC, Immune system, Cancer, Human papillomavirus infection, Republic of Ireland, Medical device, Roche, Woman, Marketing, TSX, Infection, Vaccine, EU

MISSISSAUGA, Ontario, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its quality assessment products (“QAPs™”) are supporting a testing program for Human Papilloma Virus (“HPV”) using molecular diagnostic (“MDx”) technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state.

Key Points: 
  • MISSISSAUGA, Ontario, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its quality assessment products (“QAPs™”) are supporting a testing program for Human Papilloma Virus (“HPV”) using molecular diagnostic (“MDx”) technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state.
  • Dr. Lisa Tang, Head of Sales and Marketing of MSC commented, “We are pleased to support this important women’s health initiative with Microbix’s HPV QAPs.
  • We now look forward to the roll-out of MDx-based cervical cancer screening throughout the Republic of Ireland.”
    An initial purchase order for HPV-directed QAPs has been received by Microbix and it is expected that recurring QAPs sales into Ireland will become routine.
  • Phil Casselli, Senior Vice President of Sales and Business Development of Microbix also commented, “Ireland provides an example of Microbix’s technological leadership by way of our HPV quality controls being selected to support another national HPV screening program.